These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 11086633

  • 1. Blocking the tissue renin-angiotensin system: the future cornerstone of therapy.
    Unger T, Azizi M, Belz GG.
    J Hum Hypertens; 2000 Oct; 14 Suppl 2():S23-31. PubMed ID: 11086633
    [Abstract] [Full Text] [Related]

  • 2. Persistent cardiovascular effects of chronic renin-angiotensin system inhibition following withdrawal in adult spontaneously hypertensive rats.
    Paull JR, Widdop RE.
    J Hypertens; 2001 Aug; 19(8):1393-402. PubMed ID: 11518847
    [Abstract] [Full Text] [Related]

  • 3. Putting the efficacy of candesartan cilexetil into perspective: a review of new comparative data.
    Mallion JM, Badguet JP.
    J Hum Hypertens; 2000 Oct; 14 Suppl 2():S33-41. PubMed ID: 11086634
    [Abstract] [Full Text] [Related]

  • 4. Renal responses to angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor in partially nephrectomized spontaneously hypertensive rats.
    Okada H, Suzuki H, Kanno Y, Ikenaga H, Saruta T.
    J Cardiovasc Pharmacol; 1995 Oct; 26(4):564-9. PubMed ID: 8569216
    [Abstract] [Full Text] [Related]

  • 5. Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension.
    Weber MA.
    J Hypertens Suppl; 1997 Dec; 15(6):S31-6. PubMed ID: 9493125
    [Abstract] [Full Text] [Related]

  • 6. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients.
    Fridman K, Andersson OK, Wysocki M, Friberg P, Sunzel M.
    Eur J Clin Pharmacol; 1998 Sep; 54(7):497-501. PubMed ID: 9832289
    [Abstract] [Full Text] [Related]

  • 7. Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats.
    Inada Y, Wada T, Ojima M, Sanada T, Shibouta Y, Kanagawa R, Ishimura Y, Fujisawa Y, Nishikawa K.
    Clin Exp Hypertens; 1997 Oct; 19(7):1079-99. PubMed ID: 9310205
    [Abstract] [Full Text] [Related]

  • 8. Pharmacologic properties of candesartan cilexetil--possible mechanisms of long-acting antihypertensive action.
    Inada Y, Ojima M, Kanagawa R, Misumi Y, Nishikawa K, Naka T.
    J Hum Hypertens; 1999 Jan; 13 Suppl 1():S75-80. PubMed ID: 10076925
    [Abstract] [Full Text] [Related]

  • 9. Regional hemodynamic effects of candesartan cilexetil (TCV-116), an angiotensin II AT1-receptor antagonist, in conscious spontaneously hypertensive rats.
    Kanagawa R, Wada T, Sanada T, Ojima M, Inada Y.
    Jpn J Pharmacol; 1997 Mar; 73(3):185-90. PubMed ID: 9127812
    [Abstract] [Full Text] [Related]

  • 10. Key features of candesartan cilexetil and a comparison with other angiotensin II receptor antagonists.
    Sever PS.
    J Hum Hypertens; 1999 Jan; 13 Suppl 1():S3-10; discussion S33-4. PubMed ID: 10076915
    [Abstract] [Full Text] [Related]

  • 11. [Candesartan cilexetil: pharmacological properties and protective effects against organ damage of a novel nonpeptide angiotensin II-receptor antagonist].
    Inada Y, Naka T.
    Nihon Yakurigaku Zasshi; 2000 Mar; 115(3):151-60. PubMed ID: 10876800
    [Abstract] [Full Text] [Related]

  • 12. Angiotensin II receptor blockers. A new class of antihypertensive drugs.
    Velasquez MT.
    Arch Fam Med; 1996 Jun; 5(6):351-6. PubMed ID: 8640326
    [Abstract] [Full Text] [Related]

  • 13. Comparison of the antihypertensive effects of the new angiotensin II (AT1) receptor antagonist candesartan cilexetil (TCV-116) and the angiotensin converting enzyme inhibitor enalapril in rats.
    Wada T, Inada Y, Ojima M, Sanada T, Shibouta Y, Nishikawa K.
    Hypertens Res; 1996 Jun; 19(2):75-81. PubMed ID: 10968199
    [Abstract] [Full Text] [Related]

  • 14. Effects of AT1 receptor blockade on blood pressure and the renin-angiotensin system in spontaneously hypertensive rats of the stroke prone strain.
    Wagner J, Drab M, Bohlender J, Amann K, Wienen W, Ganten D.
    Clin Exp Hypertens; 1998 Feb; 20(2):205-21. PubMed ID: 9533614
    [Abstract] [Full Text] [Related]

  • 15. Comparative effects of three sites of renin-angiotensin blockade on the regression of left ventricular hypertrophy in spontaneously hypertensive rats.
    Zhang Q, Kohara K, Qui HY, Hiwada K.
    Am J Ther; 1997 Feb; 4(5-6):199-202. PubMed ID: 10423611
    [Abstract] [Full Text] [Related]

  • 16. Role of the renin-angiotensin system in hypertension in the elderly.
    Nagano M, Higaki J, Mikami H, Ogihara T.
    Blood Press Suppl; 1994 Feb; 5():130-3. PubMed ID: 7889195
    [Abstract] [Full Text] [Related]

  • 17. Angiotensin II receptor antagonism: losartan - sites and mechanisms of action.
    Triggle DJ.
    Clin Ther; 1995 Feb; 17(6):1005-30. PubMed ID: 8750395
    [Abstract] [Full Text] [Related]

  • 18. Involvement of angiotensin II in progression of renal injury in rats with genetic non-insulin-dependent diabetes mellitus (Wistar fatty rats).
    Noda M, Matsuo T, Nagano-Tsuge H, Ohta M, Sekiguchi M, Shibouta Y, Naka T, Imura Y.
    Jpn J Pharmacol; 2001 Apr; 85(4):416-22. PubMed ID: 11388646
    [Abstract] [Full Text] [Related]

  • 19. Combined blockade of AT1-receptors and ACE synergistically potentiates antihypertensive effects in SHR.
    Raasch W, Jöhren O, Schwartz S, Gieselberg A, Dominiak P.
    J Hypertens; 2004 Mar; 22(3):611-8. PubMed ID: 15076168
    [Abstract] [Full Text] [Related]

  • 20. Involvement of angiotensin II in cardiovascular and renal injury: effects of an AT1-receptor antagonist on gene expression and the cellular phenotype.
    Kim S, Iwao H.
    J Hypertens Suppl; 1997 Dec; 15(6):S3-7. PubMed ID: 9493120
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.